Journals / Retina-Vitreus / 2014 / Cilt: 22 - Sayı: 3

short-term outcomes of aflibercept in eyes with wet age-related macular degeneration resistant to ranibizumab

Ranibizumab tedavisine dirençli yaş tip yaşa bağlı maküla dejeneresansı olgularında intravitreal aflibercept uygulamasının kısa dönem sonuçları

Pages
179–183
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Intravitreal aflibercept treatment seems to be an effective treatment of choice for eyes with wet age-related macular degeneration resistant to ranibizumab.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To report short-term results of aflibercept treatment in cases with wet age-related macular degeneration (AMD) resistant to ranibizumab.
📊
Key Findings & Data:Results: 7 eyes of 5 patients (3 women, 2 men) with a mean age of 70.8 were included in this study.
💡
Conclusion & Impact:Intravitreal aflibercept treatment seems to be an effective treatment of choice for eyes with wet age-related macular degeneration resistant to ranibizumab.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To report short-term results of aflibercept treatment in cases with wet age-related macular degeneration (AMD) resistant to ranibizumab. Materials and Methods: The patients with wet AMD who had the persistent subretinal/intraretinal fluid or pigment epithelial detachment (PED) despite previous ranibizumab treatments were included the study. The medical records of the patients were retrospectively analyzed and the demographical datas, previous treatments, best corrected visual acuities (BCVA), the central macular thickness (CMT) and precence of intraretinal/subretinal fluid and PED based on OCT before and after aflibercept injections were recorded. Results: 7 eyes of 5 patients (3 women, 2 men) with a mean age of 70.8 were included in this study. The mean number of ranibizumab injections before switching aflibercept was 12.14 (6-28). The mean follow-up after the aflibercept injections was 2.2 (1-4) months and meanwhile the mean number of aflibercept injections was 1.85 (1-3). The mean BCVA were 1.18 and 1.1 LogMAR before and after the aflibercept injections, respectively. The mean CMT were 773.8 (404-1488) and 225.7 (160- 273) microns before and after the aflibercept injections, respectively. Conclusion: Although it was not accompanied by an increase in visual acuity, in all cases after the injection of aflibercept, anatomic success was provided in the short term. These results can be explained with the presence of persistant fluid and formation of scar tissue before aflibercept treatment. Intravitreal aflibercept treatment seems to be an effective treatment of choice for eyes with wet age-related macular degeneration resistant to ranibizumab.

Özet

Amaç: Ranibizumab tedavisine dirençli yaş tip yaşa bağlı maküla dejeneresansı (YBMD) olgularında intravitreal afliber- cept uygulamasının kısa dönem sonuçlarının incelenmesi. Gereç ve Yöntem: Ankara Üniversitesi Tıp Fakültesi Göz Hastalıkları Retina Servisi’ nde yaş tip YBMD tanısı ile takip- li, intravitreal ranibizumab tedavisine rağmen optik koherens tomografide (OKT) intraretinal/ subretinal sıvı ve pigment epitel dekolmanının (PED) varlığı nedeniyle intravitreal aflibercept enjeksiyonu uygulanan ve en az bir aylık takibi olan olgular çalışmaya dahil edildi. Olguların tıbbi kayıtları retrospektif olarak incelenerek demografik verileri, aflibercept en- jeksiyonu öncesi uygulanmış olan tedaviler, aflibercept enjeksiyonu öncesi ve sonrası en iyi düzeltilmiş görme keskinliği (EİDGK), OKT ile saptanan santral maküla kalınlığı (SMK), intraretinal/subretinal sıvı ve PED varlığı kaydedildi. Bulgular: Çalışmaya 3’ü kadın 2’si erkek toplam 5 olgunun 7 gözü dahil edildi. Olguların yaş ortalaması 70.8 (62-77)’di. Aflibercept enjeksiyonu öncesi olgulara uygulanmış olan ortalama göz içi enjeksiyon sayısı 12.14 (6-28)’tü. Aflibercept en- jeksiyonu sonrası ortalama takip süresi 2.2 (1-4) ay olup bu sürede olgulara ortalama 1.85 (1-3) aflibercept enjeksiyonu uygulandı. Olguların aflibercept enjeksiyonu öncesi ve sonrası EİDGK ortalaması sırasıyla 1.18 ve 1.1 LogMAR olarak bu- lundu. Olguların aflibercept enjeksiyonu öncesi ve sonrası SMK ortalamaları sırasıyla 773.8 (404-1488) ve 225.7 (160-273) mikrondu. Sonuç: Olguların tümünde aflibercept enjeksiyonu sonrası kısa dönemde anatomik başarı sağlanmasına rağmen, görme keskinliği artışı buna eşlik etmemiştir. Bu durumu tedavi öncesinde olgulardaki uzun dönem kronik sıvı varlığı ve skar dokusunun gelişmesi açıklamaktadır. Ranibizumab tedavisine dirençli YBMD olgularında, erken dönemde intravitreal af- libercept tedavisine geçilmesi etkili bir alternatif tedavi seçeneği olarak görünmektedir.

🔖

Cite This Article

BATIOĞLU, F., DEMİREL, S., BİLİCİ, S., ÖZMERT, E. (2014). short-term outcomes of aflibercept in eyes with wet age-related macular degeneration resistant to ranibizumab. Retina-Vitreus, Cilt: 22 - Sayı: 3, 179–183. https://ajindex.com/articles/308137

References (14)

  1. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neo- vascular age-related macular degeneration. Ophthalmology 2009;116:1731-9
  2. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coher- ence tomography-guided, variable dosing regimen with intra- vitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83
  3. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Oph- thalmology 2011;118:663-71
  4. Patel RD, Momi RS, Hariprasad SM. Review of ranibizumab trials for neovascular age-related macular degeneration. Se- min Ophthalmol 2011;26:372-9
  5. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovasculariza- tion secondary to age-related macular degeneration. Ophthal- mology 2012;119:1175-83
  6. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dos- ing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58
  7. Rosenfeld PJ, Brown DM, Heier JS, et al, MARINA Study Group. Ranibizumab for neovascular age-related macular de- generation. N Engl J Med 2006;355:1419-31
  8. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-relat- ed macular degeneration: two-year results of the ANCHOR Study. Ophthalmology 2009;116:57-65
  9. Rofagha S, Bhisitkul RB, Boyer DS et al, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9
  10. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96:14-20
  11. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT.Tachyphylaxis after intravitreal bevacizumab for exuda- tive age-related macular degeneration. Retina 2009;29:723-31
  12. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8
  13. Stewart MW, Rosenfeld PJ. Predicted biological activity of in- travitreal VEGF Trap. Br J Ophthalmol 2008;92:667-8
  14. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2